Action Idorsia - 19T

Idorsia Ltd (19T) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

7,80

( 4,07% )

Prix Achat

7,735

Prix Vente

7,77

Volume échangé

3 990

7,465 Fourchette du Jour 8,19

2,23 Plage de 52 semaines 8,19

Clôture Veille

7,495

Ouverture

7,545

Dernière Transaction

7.8

Dernière heure de transaction

15:47:34

Volume moyen (3 m)

9 285

Volume financier

VWAP

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility Allschwil, Switzerland – June 26...

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon Ad hoc announcement pursuant to Art. 53 LR Senior secured...

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology...

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	1.6	25.8064516129	6.2	8.19	6.095	12605	7.10326857	DE
4	2.9980001	62.4323232493	4.8019999	8.19	4.41	10096	5.97333359	DE
12	3.975	103.921568627	3.825	8.19	3.588	9285	4.9322861	DE
26	3.08	65.2542372881	4.72	8.19	3.11	10194	4.39223991	DE
52	5.57	249.775784753	2.23	8.19	2.23	10809	4.01993521	DE
156	6.382	450.070521862	1.418	8.19	1.332	10547	3.80513614	DE
260	6.382	450.070521862	1.418	8.19	1.332	10547	3.80513614	DE

19T - Frequently Asked Questions (FAQ)

What is the current Idorsia Ltd share price?

The current share price of Idorsia Ltd is 7,80 €

What is the 1 year trading range for Idorsia Ltd share price?

Idorsia Ltd has traded in the range of 2,23 € to 8,19 € during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Idorsia Ltd (19T)

Idorsia Ltd (19T) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

19T Dernières nouvelles

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

Idorsia announces the nomination of three candidates for election to the Board of Directors

19T - Frequently Asked Questions (FAQ)

19T Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Idorsia Ltd (19T)

Idorsia Ltd (19T) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

19T Dernières nouvelles

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

Idorsia announces the nomination of three candidates for election to the Board of Directors

19T - Frequently Asked Questions (FAQ)

19T Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités